• Alvotech published annual report for year ended Dec. 31, 2025, highlighting expansion of launched biosimilar portfolio alongside progress in late-stage pipeline.
• U.S. launch of SELARSDI (AVT04, ustekinumab) started in February 2025 through partner Teva.
• FDA issued Complete Response Letters for AVT05 in October 2025, AVT06 in November 2025, AVT03 in December 2025, citing findings from July 2025 pre-license inspection of Reykjavik facility.
• Remediation plan started for Reykjavik site, with BLAs expected to be resubmitted once facility observations are addressed.
• Commercial footprint broadened via partnerships, including expanded Advanz collaboration on multiple candidates, strategic U.S. commercialization agreement with Alvogen for AVT10, AVT32, AVT48.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.